Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer.

2002104 citationsJournal Article

Authors

William D. Fox · Cedars-Sinai Medical Center

Brian Higgins

Abstract

rhu alpha VEGF has cytostatic clinical activity in this androgen-independent prostate cancer xenograft model, and the addition of paclitaxel demonstrates increased clinical activity.

Topics & Keywords

Angiogenesis and VEGF in Cancer Cancer, Hypoxia, and Metabolism Prostate Cancer Treatment and Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: PubMed

Volume 8, Issue 10, pp. 3226-31

Field-Weighted Citation Impact: 1.89